poisar

Stocks · News reference

8-K filing — Protalix BioTherapeutics, Inc. (PLX)

Aug 12, 2026, 10:59 AMSEC EDGAR

Filed: 2026-08-12 AccNo: 0001104659-26-094433 Size: 394 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PLX
Source
edgar
Observed
Aug 12, 2026, 10:59 AM
Checked
Aug 12, 2026, 10:59 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 19, 2026, 2:08 PMMotley Fool Transcribing

    Protalix (PLX) Q2 2026 Earnings Call Transcript

    Protalix reported Q2 2026 revenues of $19.9 million, up from $15.7 million year-over-year, driven by Elfabrio sales through its Chiesi partnership. The company posted net income of $3.8 million ($0.05 per share) and H1 net income of $22.1 million. Full-year 2026 revenue guidance remains $78-83 million. The company maintains a strong cash position of $40.7 million with zero debt and expects PRX-115 Phase 2 RELEASE study top-line results in H2 2027.

    Read original at the-motley-fool
    PLXPFE